Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.
Cerus Corporation develops and supplies blood-safety technologies and pathogen-protected blood components for blood centers and hospitals. Its recurring news centers on the INTERCEPT Blood System for platelets and plasma, the U.S. INTERCEPT Blood System for Cryoprecipitation used to produce INTERCEPT Fibrinogen Complex, and the company’s red blood cell pathogen-reduction program.
Company updates commonly cover product revenue, gross margin trends, revenue guidance, government contract activity, international supply agreements, clinical studies involving pathogen-inactivated platelets, regulatory and pipeline developments, healthcare conference participation, and governance changes. Commercial disclosures often emphasize demand for INTERCEPT Fibrinogen Complex and adoption of pathogen inactivation technologies by blood establishments in the United States, Europe and other markets.
Cerus Corporation (CERS) will release its second quarter 2022 financial results on August 4, 2022, post-market. A conference call is scheduled for 4:30 PM ET to discuss the results and business outlook. The company focuses on safeguarding the global blood supply, with its INTERCEPT Blood System approved for platelets and plasma. The red blood cell system is undergoing regulatory review in Europe and clinical development in the US. A replay of the call will be available on the company's website.
Cerus Corporation (NASDAQ: CERS) announced the appointment of Dr. Hua Shan to its Board of Directors. Dr. Shan, a renowned expert in transfusion medicine with over 25 years of experience, aims to enhance Cerus' efforts in the Chinese market for its INTERCEPT Blood System. The Board Chair, Daniel Swisher, expressed confidence that Dr. Shan's extensive knowledge will positively impact Cerus' global presence and product safety initiatives. Dr. Shan previously served in key roles at prestigious institutions, including Stanford Medical Center and Johns Hopkins University.
Summary not available.
Cerus Corporation (CERS) reported a strong first-quarter 2022 performance with total revenue of $43.0 million, reflecting a 46% year-over-year increase. Product revenue reached $37.4 million, up 60% year-over-year. The company improved its 2022 product revenue guidance to a range of $160-165 million, a 22%-26% increase over 2021. Net loss decreased to $12.3 million from $17.5 million the previous year. Notable contracts include a multi-year agreement with the American Red Cross for INTERCEPT Platelet kits, reinforcing strong demand in the U.S.
Cerus Corporation has secured a ten-year deal with Fresenius Kabi to produce INTERCEPT Blood System sets, replacing the current contract that expires in July 2025. This collaboration aims to meet increasing global demand and enhance supply chain reliability. Manufacturing will expand to new facilities in the Caribbean and continue in France, ensuring redundancy and higher production volumes. This partnership is expected to deliver significant benefits for customers and shareholders, reinforcing Cerus' commitment to pathogen reduction in transfusion medicine.
Cerus Corporation has secured a five-year agreement with the American Red Cross to supply the INTERCEPT Blood System for Platelets. This contract aims to enhance patient access to pathogen-reduced platelets, reinforcing the Red Cross's commitment to blood safety. As the largest blood provider in the U.S., collecting over 4.6 million donations in 2021, the Red Cross will continue using Cerus' technology to meet FDA safety standards. This partnership is expected to ensure the availability of safe blood transfusions for hospitals, physicians, and patients nationwide.
Cerus Corporation (CERS) will release its first quarter 2022 financial results on May 5, 2022, post-market close. A conference call and webcast will occur at 4:30 P.M. ET to discuss the results and provide a business overview. The INTERCEPT Blood System, crucial for pathogen protection in blood components, is marketed globally, with the red blood cell system under regulatory review in Europe. The company aims to enhance blood safety and solidify its position as a global leader.
Cerus Corporation (NASDAQ: CERS) announced that CFO Kevin D. Green will participate in the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 1:30 p.m. EST. A live webcast will be accessible on the company's Investor Relations page, with a replay available for two weeks post-event. Cerus focuses on ensuring the safety of the global blood supply with products like the INTERCEPT Blood System, which is FDA-approved for platelets and plasma and under review for red blood cells in Europe. More details can be found on their website.
Cerus Corporation (CERS) reported a robust Q4 2021 with total revenues of $50.1 million, up 49% year-over-year, driven by a 41% increase in product revenues to $39.9 million. The full-year revenue reached $159.5 million, a 40% increase from 2020. The company reiterated its 2022 product revenue guidance of $157-$164 million, indicating expected growth of 20%-25%. Notably, government contract revenues surged by 90% to $10.2 million in Q4. However, net loss narrowed to $9.1 million, down from $14.4 million in Q4 2020.
Cerus Corporation (NASDAQ: CERS) will release its fourth quarter and full-year 2021 financial results on February 22, 2022, post-market close. A conference call will follow at 4:30 P.M. ET, providing insights into the company’s performance and future outlook. Investors can access the live webcast on Cerus’ Investor Relations page or by calling U.S. (866) 235-9006 or international (631) 291-4549.
Additionally, a replay will be available post-call through March 8, 2022.